Investigational Drug Targets Sleep Apnea and Nocturnal Hypertension
A phase 2 trial will evaluate the drug’s potential to reduce upper airway obstruction and nocturnal hypertension in patients with moderate-to-severe OSA.
Read MoreA phase 2 trial will evaluate the drug’s potential to reduce upper airway obstruction and nocturnal hypertension in patients with moderate-to-severe OSA.
Read MoreSurgeon-scientists analyze the case of Lawrence Faucette, the second recipient of a genetically modified pig heart, to identify challenges to avoid rejection in future xenotransplants.
Read MoreA new study reveals that sugary drinks contribute to 3.4 million new cases of diabetes and heart disease annually worldwide.
Read MoreThe American Heart Association issues a reminder about the heart risks associated with snow shoveling.
Read MoreUniversity of Virginia researchers are developing a noninvasive MRI technique to analyze the composition of fat surrounding the heart.
Read More